Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|July 25, 2014
Prioritized current unmet needs for antibacterial therapiesB Spellberg, D ShlaesLife Sciences|September 19, 2000
The cutaneous citadel: a holistic view of skin and immunityB SpellbergHematology/Oncology Clinics of North America|November 30, 1999
Autologous bone marrow transplantation in acute leukemiaB Spellberg, G J SchillerClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2000
Type 1/Type 2 immunity in infectious diseasesB Spellberg, J E EdwardsClinical Pharmacology and Therapeutics|September 15, 2016
Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the GoodB Spellberg, K A Marr, E P BrassArchives of Internal Medicine|December 1, 2001
mtDNA disease in the primary care settingB Spellberg, R M Carroll, E Robinson, et al.Infection and Immunity|November 1, 1995
Reduced virulence of Candida albicans PHR1 mutantsM A Ghannoum, B Spellberg, S M Saporito-Irwin, et al.Antimicrobial Agents and Chemotherapy|January 1, 1997
A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibioticsQ C Truong, J C Nguyen Van, D Shlaes, et al.The Biochemical Journal|February 1, 1996
Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB typeD Billot-Klein, D Shlaes, D Bryant, et al.Journal of Bacteriology|August 1, 1997
Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycinD Billot-Klein, D Shlaes, D Bryant, et al.Pageof 2